01 February 2006
Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy
Carl-Gustav Olsson, Carl-Gustav Olsson, Berit Olsson, Pernilla Magnusson, Pernilla Magnusson, Margareta S Carlsson, Marika BajcMed Sci Monit 2006; 12(2): PI9-13 :: ID: 445251
Abstract
Background: Out-of-hospital treatment of patients with deep-vein thrombosis(DVT) is routine in many countries regardless of frequent concomitant asymptomatic pulmonary embolism(PE) in this group. However, patients with symptoms and verified PE are still regularly treated in hospital.The objectives were to test a model for outpatient tinzaparin therapy and to evaluate its safety andefficacy in patients with symptomatic, small or medium-sized PE using quantitative ventilation/perfusionscintigraphy (qV/P SCINT) for patient selection and follow up. Material/Methods: This prospective studyincluded 102 patients treated with tinzaparin and warfarin for 5 days at a patient hotel. PE was quantifiedscintigraphically as loss of perfusion with preserved ventilation at segmental or subsegmental levels(mismatch). Points were attributed to segments of reduced ventilation (RoVent) and perfusion (RoPer).A holistic principle of interpretation was applied. Patients were excluded if they had >14 RoPer points(7 segments) or >7 RoVent points. Clinical follow-up and scintigraphy were repeated at discharge in 100patients and after 13 months on average. Results: Embolism diminished by 44% after 5 days and demandingsymptoms declined. There was no thromboembolic mortality in the trial. At late follow-up, PE had notrecurred in patients with resolution after 5 days. In those with insufficient early response, persistentperfusion defects were usually observed. Conclusions: The results indicate the safety and efficacy ofoutpatient treatment of PE according to our model and merit larger, multicenter, controlled studies.
Keywords: Ambulatory Care, Fibrinolytic Agents - therapeutic use, Heparin, Low-Molecular-Weight - therapeutic use, Prospective Studies, Pulmonary Embolism - radionuclide imaging, Radiopharmaceuticals - diagnostic use, Technetium Tc 99m Pentetate - diagnostic use, Ventilation-Perfusion Ratio
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952